biotech / news / / Newsmax
After President Donald Trump's showdown with pharma titans Eli Lilly and Novo Nordisk last month, a seismic shift has unfolded.
Eli Lilly and Novo Nordisk have agreed to lower U.S. prices for Ozempic and Wegovy.
KEY POINTS
- The new pricing aligns American costs for these weight-loss drugs with those in other countries.
- A government-backed pact now permits these drugs to be accessed through Medicare and Medicaid.
- The TrumpRx site has launched to facilitate broader public access to weight-loss medications.
COMPANIES
Summarized by Newsio from Newsmax. How we summarize →